Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 63.17
-0.85 (-1.33%)
At close: Sep 30, 2026
SHE:301075 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,054 | 4,711 | 1,419 | 2,134 | 2,587 | 3,113 | |
Market Cap Growth | 59.69% | 232.05% | -33.50% | -17.53% | -16.89% | - |
Enterprise Value | 5,384 | 5,025 | 1,303 | 1,851 | 2,116 | 2,503 |
Last Close Price | 63.17 | 59.67 | 17.97 | 26.49 | 32.12 | 37.76 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 113.18 | 126.19 | 45.44 |
PS Ratio | 35.28 | 30.56 | 5.90 | 6.38 | 6.45 | 5.88 |
PB Ratio | 7.22 | 7.56 | 1.88 | 2.60 | 3.43 | 3.95 |
P/TBV Ratio | 9.26 | 9.83 | 2.45 | 2.91 | 3.54 | 4.01 |
P/FCF Ratio | - | - | - | - | - | 72.72 |
P/OCF Ratio | - | - | - | 171.88 | 2296.41 | 64.65 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 37.59 | 32.59 | 5.42 | 5.54 | 5.28 | 4.72 |
EV/EBITDA Ratio | - | - | - | 117.47 | 128.68 | 32.90 |
EV/EBIT Ratio | - | - | - | - | 1167.41 | 40.12 |
EV/FCF Ratio | - | - | - | - | - | 58.47 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.51 | 0.69 | 0.72 | 0.22 | 0.13 | 0.03 |
Debt / EBITDA Ratio | - | - | - | 11.02 | 5.76 | 0.27 |
Debt / FCF Ratio | - | - | - | - | - | 0.48 |
Net Debt / Equity Ratio | 0.42 | 0.52 | 0.18 | -0.37 | -0.54 | -0.75 |
Net Debt / EBITDA Ratio | -6.27 | -4.80 | -2.21 | -19.21 | -24.60 | -7.76 |
Net Debt / FCF Ratio | -1.54 | -2.21 | -1.25 | 26.85 | 12.80 | -13.79 |
Asset Turnover | 0.10 | 0.11 | 0.19 | 0.34 | 0.46 | 0.87 |
Inventory Turnover | 1.71 | 2.28 | 3.77 | 3.22 | 4.35 | 4.90 |
Quick Ratio | 0.38 | 0.48 | 1.04 | 4.49 | 4.19 | 11.36 |
Current Ratio | 0.66 | 0.74 | 1.24 | 5.02 | 4.48 | 11.61 |
Return on Equity (ROE) | -9.93% | -19.23% | -10.80% | 2.17% | 2.41% | 12.80% |
Return on Assets (ROA) | -4.43% | -5.18% | -4.21% | -0.16% | 0.13% | 6.38% |
Return on Invested Capital (ROIC) | -9.74% | -12.72% | -12.48% | -0.46% | 0.59% | 30.35% |
Return on Capital Employed (ROCE) | -11.90% | -13.90% | -8.60% | -0.30% | 0.20% | 7.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.95% | -2.17% | -4.42% | 0.88% | 0.79% | 2.20% |
FCF Yield | -3.74% | -3.13% | -7.62% | -0.53% | -1.22% | 1.38% |
Dividend Yield | - | - | - | 0.47% | - | 1.65% |
Payout Ratio | - | - | - | 17.26% | 247.95% | 1.68% |
Buyback Yield / Dilution | -2.44% | 0.16% | -0.99% | 0.39% | -20.86% | -8.52% |
Total Shareholder Return | -2.44% | 0.16% | -0.99% | 0.86% | -20.86% | -6.87% |